Lifecycle Extension Through Ophthalmic Drug Delivery Innovation via Reformulation & Repurposing of drug molecules

• Development of a novel swollen micelle microemulsion (SMM) technology to enhance solubility and room-temperature stability of latanoprost
• Elimination of high benzalkonium chloride (BAK) dependency, reducing potential ocular surface safety concerns associated with chronic therapy
• Improved patient convenience through removal of cold-chain storage requirements and enhanced formulation tolerability.
• Successful progression from formulation concept through clinical development, regulatory approval, and commercialization, illustrating the value of drug delivery-driven lifecycle management

Speakers:

Ajay Khopade

Vice President, Head of Formulation Non-Orals & Analytical, & R&D Site Head

Sun Pharmaceutical Industries